Heat Seeking $25M; Sets Range for Proposed IPO
By Jennifer Boggs
Tuesday, July 9, 2013
Heat Biologics, a firm founded in 2008 to develop an off-the-shelf allogeneic immunotherapy technology based on heat-shock proteins, is taking its place in biotech's bustling initial public offering (IPO) queue.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.